Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/ nucleotide analogue treatment among Chinese chronic hepatitis B patients
Free accessResearch articleFirst published online November, 2010
Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/ nucleotide analogue treatment among Chinese chronic hepatitis B patients
Antiviral drug-resistant HBV mutants under a variety of treatment protocols are complex and only partly understood. Here, a population-based cross-sectional study was performed to analyse the profile of resistance mutations in distinct evolutionary pathways refractory to different nucleoside/nucleotide analogues (NAs).
Methods
Serum samples of 199 chronic hepatitis B patients undergoing NA treatment from five hospitals in four northern cities of China were obtained between January 2007 and July 2009. The genotypic resistance of HBV in these samples was characterized. The full-length HBV reverse transcriptase region was amplified, sequenced and analysed with particular focus on the following NA-resistant changes: rtL80, rtI169, rtV173, rtL180, rtA181, rtT184, rtA194, rtS202, rtM204, rtN236 and rtM250.
Results
Among 199 HBV isolates, 30 (15.08%) and 169 (84.92%) were genotypes B and C, respectively, and 65 (32.66%) harboured NA-resistant mutations. The prevalence of mutations at rtM204 was 34.33% in 134 patients who had received or who had been exposed to lamivudine-based therapy. Five cases of rtN236 mutations were detected exclusively among 75 patients receiving adefovir-dipivoxil-based therapies. A total of 19 cases of multidrug resistance rtA181 mutations were observed in those with lamivudine-, adefovir-dipivoxil- or telbivudine-based treatment (186 cases), but not in those undergoing entecavir treatment (13 cases). Mutations were not found at rtI169, rtT184, rtA194 or rtS202. rtM204 mutations (27 rtM204I, 15 rtM204V and 5 rtM204I/V cases) were detected at the highest frequency among 65 mutants (72.30% [47/65]) and found to display 16 combination mutation patterns, in which rtM204I and rtM204V were significantly associated with rtL80I/V and rtL180M, respectively (P<0.01).
Conclusions
One-third of the studied population harboured NA-resistant HBV with complicated mutation patterns. Monitoring HBV genotypic resistance mutation markers and patterns is therefore shown to be beneficial for optimizing antiviral therapies and for avoiding clinical deterioration.
References
1.
LeungN.W., LaiC.L., ChangT.T.Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.Hepatology2001; 33: 1527–1532.
2.
MarcellinP., ChangT.T., LimS.G.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med2003; 348: 808–816.
3.
LokA.S., ZoulimF., LocarniniS.Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.Hepatology2007; 46: 254–265.
4.
LocarniniS., MasonW.S.Cellular and virological mechanisms of HBV drug resistance.J Hepatol2006; 44: 422–431.
5.
Chinese Society of Hepatology, Chinese Medical Association and Chinese Society of Infectious Diseases, Chinese Medical Association.Guideline on prevention and treatment of chronic hepatitis B in China.Chin Med J (Engl)2007; 120: 2159–2173.
LokA.S.Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here yet?J Hepatol2009; 51: 416–418.
8.
MarcellinP., HeathcoteE.J., ButiM.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.N Engl J Med2008; 359: 2442–2455.
9.
LocarniniS.Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure.Hepatol Int2008; 2: 147–151.
10.
StuyverL.J., LocarniniS.A., LokA.Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.Hepatology2001; 33: 751–757.
11.
Borroto-EsodaK., MillerM.D., ArterburnS.Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials.J Hepatol2007; 47: 492–498.
12.
LiuB.M., LiT., XuJ.Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment naïve Chinese patients.Antiviral Res2010; 85: 512–519.
13.
ZoulimF.Detection of hepatitis B virus resistance to antivirals.J Clin Virol2001; 21: 243–253.
14.
ShawT., BartholomeuszA., LocarniniS.HBV drug resistance: mechanisms, detection and interpretation.J Hepatol2006; 44: 593–606.
15.
LangleyD.R., WalshA.W., BaldickC.J.Inhibition of hepatitis B virus polymerase by entecavir.J Virol2007; 81: 3992–4001.
16.
LaiC.L., LeungN., TeoE.K.A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.Gastroenterology2005; 129: 528–536.
17.
ZoulimF., DurantelD., DenyP.Management and prevention of drug resistance in chronic hepatitis B.Liver Int2009; 29: 108–115.
18.
VilletS., PichoudC., BillioudG.Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.J Hepatol2008; 48: 747–755.
19.
CiancioA., SmedileA., RizzettoM., LaggetM., GerinJ., KorbaB.Identification of HBV DNA sequences that are predictive of response to lamivudine therapy.Hepatology2004; 39: 64–73.
20.
SvicherV., GoriC., TrignettiM.The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.J Hepatol2009; 50: 461–470.
21.
de FranchisR., HadengueA., LauG.EASL International Consensus Conference on Hepatitis B. 13–14 September 2002, Geneva, Switzerland.J Hepatol2003; 39 Suppl 1: S3–S25.
LiuY., WangC.M., ChengJ.Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility.Chin Med J (Engl)2009; 122: 1585–1586.
24.
BaldickC.J., TenneyD.J., MazzuccoC.E.Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance.Hepatology2008; 47: 1473–1482.
25.
SheldonJ., CaminoN., RodésB.Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.Antivir Ther2005; 10: 727–734.
26.
ColonnoR.J., RoseR., BaldickC.J.Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.Hepatology2006; 44: 1656–1665.
27.
TenneyD.J., LevineS.M., RoseR.E.Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine.Antimicrob Agents Chemother2004; 48: 3498–3507.
28.
ThibaultV., Aubron-OlivierC., AgutH., KatlamaC.Primary infection with a lamivudine-resistant hepatitis B virus.AIDS2002; 16: 131–133.
29.
YimH.J., HussainM., LiuY., WongS.N., FungS.K., LokA.S.F.Evolution of multi-drug resistant hepatitis B virus during sequential therapy.Hepatology2006; 44: 703–712.
30.
LeeY.S., ChungY.H., KimJ.A.Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy.Liver Int2009; 29: 552–556.
31.
WarnerN., LocarniniS., KuiperM.The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.Antimicrob Agents Chemother2007; 51: 2285–2292.
32.
SeiferM., PattyA., SerraI., LiB., StandringD.N.Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.Antiviral Res2009; 81: 147–155.
33.
TenneyD.J., RoseR.E., BaldickC.J.Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.Antimicrob Agents Chemother2007; 51: 902–911.
